Streptococcus Agalactiae Infection
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
MinervaXDenmark - Copenhagen
2 programs2
GBS-NN/NN2 vaccinePhase 2/3Vaccine1 trial
GBS-NN/NN2 vaccinePhase 2/3Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
MinervaXGBS-NN/NN2 vaccine
MinervaXGBS-NN/NN2 vaccine
Clinical Trials (2)
Total enrollment: 902 patients across 2 trials
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
Start: Mar 2025Est. completion: Jun 2029338 patients
Phase 2/3Active Not Recruiting
GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age
Start: Dec 2024Est. completion: Jun 2025564 patients
Phase 2/3Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.